MEDINEX LIMITED (OTX) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of MEDINEX LIMITED S$0.32, price S$0.20, upside +61.6%, quality 76 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch MEDINEX LIMITED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Medinex Limited, an investment holding company, provides professional support services to medical clinics in Singapore. It operates through four segments: Medical Support Services, Business Support Services, Pharmaceutical Services, and Medical Services.
Show more
Medinex Limited, an investment holding company, provides professional support services to medical clinics in Singapore. It operates through four segments: Medical Support Services, Business Support Services, Pharmaceutical Services, and Medical Services. The company engages in the setting up of clinics, facilitating applications for relevant clinic licenses, value added services to healthcare sectors, turnkey solutions, as well as strategic advice to general practitioners and specialists on establishing clinic facilities. It also provides accounting and tax agent, human resource management, and corporate secretarial services, as well as business support services, such as accounting, tax agent, human resource management, and corporate secretarial services to various sectors, such as food and beverage, retail, education, and beauty. In addition, the company procures medical and pharmaceutical products to clinics. Further, the company offers diagnostic and x-rays, pre-employment check-ups, vaccination, customized healthcare plans, and health screening services in clinics. Additionally, it provides advisory services, and business and management consultancy services, call support services, and data protection officer services to its customers; and training services. Medinex Limited was incorporated in 2009 and is headquartered in Singapore.
Stock analysis
MEDINEX LIMITED (OTX) currently trades at 0.1980 SGD, while our model-based Fair Value estimate is 0.3200 SGD, implying the stock looks roughly 38.1% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 0.3000 SGD per share, and 19 of the 22 models we run sit above the 0.1980 SGD price.
Bear case: the Asset-Based group reads lowest at 0.0800 SGD, and 3 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.2400 SGD (bear) to 0.4500 SGD (bull), the price of 0.1980 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 76/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
MEDINEX LIMITED reported revenue of 12.4M SGD in FY2026 versus 12.0M SGD in FY2022, a compound +0.9%/yr. Reported net income was 2.2M SGD in FY2026, compounding −5.7%/yr from FY2022.
Key figures
Market cap 26.6M SGD (≈ $20.8M) · P/E ratio 9.9 · P/S ratio 1.77 · EPS (TTM) 0.0200 SGD · Dividend yield 8.6% · Net margin 17.9% · Return on equity 13.4% · Return on assets (EBIT) 18.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 21% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 62%, OTX screens cheaper than that median.
Fair Value models
Bear 0.2400 SGDFair Value 0.3200 SGDBull 0.4500 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (0.0015 SGD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−3.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
Start year 2021 (pandemic)
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+1.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.2%
Dividend (yield on the price)8.6%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −9.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score75 · Top 25%
Fair Value upside+61.6% · Top 25%
Profitability
Return on equity (TTM)13.4% · Above median
Return on assets7.1% · Top 25%
Net margin (TTM)17.9% · Top 25%
Operating margin (TTM)15.3% · Top 25%
Growth and dividend
Revenue growth−3.0% · Bottom 25%
Dividend yield (TTM)8.6% · Top 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "MEDINEX LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/OTX
Frequently asked questions
Is MEDINEX LIMITED (OTX) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 0.3200 SGD versus a price of 0.1980 SGD, about +62% upside (undervalued).
What is the fair value of OTX?
Our model-based fair value for MEDINEX LIMITED is 0.3200 SGD (as of Oct 3, 2026), built from audited fundamentals. The current price: 0.1980 SGD.
What is the quality score of OTX?
MEDINEX LIMITED has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MEDINEX LIMITED (OTX)?
Our model-based price target is the fair value of 0.3200 SGD (as of Oct 3, 2026) from 22 valuation models. Cautious scenario 0.2400 SGD, optimistic scenario 0.4500 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the MEDINEX LIMITED stock forecast for 2026?
Our models put fair value at 0.3200 SGD, about +62% upside versus a price of 0.1980 SGD (undervalued). Cautious scenario 0.2400 SGD, optimistic scenario 0.4500 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of MEDINEX LIMITED (OTX)?
MEDINEX LIMITED reported trailing-twelve-month revenue of about 12.4M SGD (latest available figure, as of Oct 3, 2026).
Does MEDINEX LIMITED pay a dividend?
MEDINEX LIMITED currently shows a dividend yield of about 8.59% relative to its recent price (as of Oct 3, 2026).
What growth is priced into MEDINEX LIMITED (OTX)?
For today's price to be fair in a discounted-cash-flow model, MEDINEX LIMITED would have to grow free cash flow by -7.8 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.9 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of OTX use?
Our models discount MEDINEX LIMITED at 8.3 %: a base by market capitalisation (nano), damped by beta 0.13, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MEDINEX LIMITED that is -7.8 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has MEDINEX LIMITED (OTX) delivered so far?
Over the past 5 years revenue at MEDINEX LIMITED grew +2.9 % a year. The price currently implies -7.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MEDINEX LIMITED (OTX) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into MEDINEX LIMITED (-7.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MEDINEX LIMITED (OTX)?
The free-cash-flow yield on the price is 9.57 %: that much free cash flow MEDINEX LIMITED produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MEDINEX LIMITED (OTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MEDINEX LIMITED it is 0.3200 SGD per share (as of Oct 3, 2026), against a price of 0.1980 SGD. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is MEDINEX LIMITED stock overvalued or undervalued in 2026?
As of Oct 3, 2026, OTX trades below its calculated fair value: price 0.1980 SGD, fair value 0.3200 SGD, a gap of about +62% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OTX?
No. The price is what the market pays today (0.1980 SGD); the fair value is what the company's own numbers justify (0.3200 SGD). For MEDINEX LIMITED the two are 0.1220 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is MEDINEX LIMITED worth?
The market values MEDINEX LIMITED at about 26.6M SGD (market capitalisation, as of Oct 3, 2026). Per share that is 0.1980 SGD; our models calculate a fair value of 0.3200 SGD per share.
What do the bullish and bearish scenarios say about OTX?
Our models span a range for MEDINEX LIMITED: cautious scenario 0.2400 SGD, base 0.3200 SGD, optimistic 0.4500 SGD per share (as of Oct 3, 2026, price 0.1980 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OTX?
MEDINEX LIMITED trades at a price-to-earnings ratio of 9.9 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.3200 SGD is built from several models across several years. Other multiples: P/B 1.5, P/S 1.9, EV/EBITDA 8.6.
How solid is the balance sheet of MEDINEX LIMITED (OTX)?
Balance-sheet figures for MEDINEX LIMITED (as of Oct 3, 2026): return on equity 13.4%. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is OTX from its 52-week high?
MEDINEX LIMITED trades at 0.1980 SGD, about 21% below its 52-week high of 0.2500 SGD and 4% above the low of 0.1900 SGD (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of 0.3200 SGD is for.
Which stocks are comparable to MEDINEX LIMITED?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MEDINEX LIMITED stock attractive at the current price?
The data as of Oct 3, 2026: price 0.1980 SGD, calculated fair value 0.3200 SGD (+62%), Quality Score 76/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OTX calculated?
We run MEDINEX LIMITED through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.3200 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. MEDINEX LIMITED currently trades 38 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MEDINEX LIMITED (OTX)?
The closing price on Sep 30, 2026 was 0.1980 SGD. Our model-based fair value is 0.3200 SGD, about +62% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MEDINEX LIMITED right now?
The rarer combination: high quality (76/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (0.2400 SGD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.2400 SGD to 0.4500 SGD) leaves room in how you read the outcome.
Key figures of MEDINEX LIMITED
How large is the market capitalisation of MEDINEX LIMITED (OTX)?
The market capitalisation of MEDINEX LIMITED is 26.6M SGD (≈ $20.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MEDINEX LIMITED (OTX)?
The price-to-sales ratio of MEDINEX LIMITED is 1.77 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MEDINEX LIMITED (OTX)?
Earnings per share at MEDINEX LIMITED are 0.0200 SGD (price ÷ EPS = P/E 9.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of MEDINEX LIMITED (OTX)?
The dividend yield of MEDINEX LIMITED is 8.6% (payout 85.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of MEDINEX LIMITED (OTX)?
The net margin of MEDINEX LIMITED is 17.9% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MEDINEX LIMITED (OTX)?
The return on equity (ROE) of MEDINEX LIMITED is 13.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MEDINEX LIMITED (OTX)?
On an EBIT basis the return on assets of MEDINEX LIMITED is 18.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MEDINEX LIMITED (OTX)?
The operating margin of MEDINEX LIMITED is 24.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MEDINEX LIMITED (OTX)?
Revenue at MEDINEX LIMITED is growing −2.4% versus a year earlier (3y avg −1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MEDINEX LIMITED (OTX)?
Earnings per share at MEDINEX LIMITED are growing −90.8% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch MEDINEX LIMITED in the live analysis
One click puts MEDINEX LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
